AstraZeneca: expands oncology partnership with Proteros

(CercleFinance.com) - The German company Proteros announced on Monday that it will deepen its oncology collaboration with biopharmaceutical giant AstraZeneca.


The new step, which builds on an existing partnership formed last year, involves the development of small-molecule inhibitors targeting a second epigenetic protein associated with cancer.

While genetics focuses on the study of genes, epigenetics considers a "layer" of additional information that defines how those genes will or will not be used by cells.

The new agreement will provide Proteros with funding for research activities, which could be supplemented by milestone payments of 75 million euros, as well as royalties on future drug sales.


Copyright (c) 2022 CercleFinance.com. All rights reserved.